SCHEMBL5008249

SCHEMBL5008249

CN(C)C(=O)Nc1cccc(CNC(=O)c2cc(NC(=O)c3cc(F)c(F)cc3Cl)[nH]n2)c1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
PPARG P37231 8/20 0.47
AURKA O14965 5/20 0.42
AURKB Q96GD4 5/20 0.42
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
RPS6KB1 P23443 1/20 0.39
CYP2C19 P33261 1/20 0.39
CDK14 O94921 1/20 0.39
CCNY Q8ND76 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010715 0.90 PPARG (0.49) ALDH1A1PPARGAURKAAURKBLMNA
SCHEMBL5008544 0.90 PPARG (0.47) ALDH1A1PPARGNPC1RAB9ACYP2C19
SCHEMBL14587823 0.89 PPARG (0.48) ALDH1A1PPARGAURKAAURKBLMNA
Hydrochloric Acid SCHEMBL5010431 0.88 PPARG (0.47) ALDH1A1PPARGAURKAAURKBLMNA
SCHEMBL5012080 0.86 PPARG (0.45) ALDH1A1PPARGLMNANPC1RAB9A
SCHEMBL5013521 0.86 PPARG (0.47) ALDH1A1PPARGAURKAAURKBLMNA
SCHEMBL5010362 0.85 PPARG (0.50) ALDH1A1PPARGLMNAGAANPC1
SCHEMBL5013675 0.85 PPARG (0.48) ALDH1A1PPARGAURKAAURKB
SCHEMBL5012134 0.85 PPARG (0.48) ALDH1A1PPARGLMNANPC1
SCHEMBL5010756 0.84 PPARG (0.48) ALDH1A1PPARGAURKAAURKBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL ALDH1A1 1278/4885PPARG 706/4885AURKA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.